Advertisement

Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam.

01:43 EDT 22nd May 2013 | BioPortfolio

Summary of "Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam."

We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease. Under continuous video-EEG monitoring, the clinical myoclonic status and the electrographic ictal discharges resolved within 10 minutes after the infusion was initiated. The patient tolerated the treatment well without any reported side effects. This case suggests that levetiracetam may be a safe, effective, and well tolerated intravenous drug in patients with metabolic myoclonic status epilepticus such as Gaucher disease.

Affiliation

Epilepsy Center, Neurological Institute, University Hospitals Case Medical Center, Cleveland, Ohio.

Journal Details

This article was published in the following journal.

Name: Epileptic disorders : international epilepsy journal with videotape
ISSN: 1294-9361
Pages:

Links

Medical and Biotech [MESH] Definitions

Status Epilepticus

A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)

Paraldehyde

A hypnotic and sedative with anticonvulsant effects. However, because of the hazards associated with its administration, its tendency to react with plastic, and the risks associated with its deterioration, it has largely been superseded by other agents. It is still occasionally used to control status epilepticus resistant to conventional treatment. (From Martindale, The Extra Pharmacopoeia, 30th ed, p608-9)

Epilepsies, Myoclonic

A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic (i.e., occurring secondary to known disease processes such as infections, hypoxic-ischemic injuries, trauma, etc.).

Disease-free Survival

Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.

Gaucher Disease

An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.

PubMed Articles [ 21819 Associated PubMed Articles listed on BioPortfolio]

Sixteen years of prenatal consultations for the N370S/N370S Gaucher disease genotype: What have we learned?

OBJECTIVE: Although prenatal diagnosis and genotyping are available for Gaucher disease, genetic counseling for an affected child's parents reflects the inability to predict disease course with certai...

The uncommon causes of status epilepticus: A Systematic Review.

This paper reports the first systematic review of uncommon causes of status epilepticus reported in the literature between 1990 and 2008. Uncommon causes are defined as those not listed in the main ep...

Treatment of Nonconvulsive Status Epilepticus.

OPINION STATEMENT: Status epilepticus is a neurologic emergency with significant potential morbidity and even mortality. It should be diagnosed and treated as quickly as possible, with concurrent rapi...

Clinical Reasoning: A 10-month-old boy with myoclonic status epilepticus.

Partial status epilepticus induced by hypocupremia in a patient with Wilson's disease.

Although seizures are rarely encountered in Wilson's disease (WD), seizures related to hypocupremia have not been reported before. We report a patient presenting with partial status epilepticus who wa...

Clinical Trials [ 3685 Associated Clinical Trials listed on BioPortfolio]

Treatment of Refractory Status Epilepticus

The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard...

Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus

The purpose of this study is to determine whether levetiracetam is safe and well tolerated by patients while suffering a status epilepticus. Levetiracetam is added to the standard treatmen...

Lorazepam for the Treatment of Status Epilepticus in Children

The purpose of this study is to gather the data to: 1) determine the best dose, and 2) evaluate its effectiveness and safety in stopping seizures. Part 1 is a pharmacokinetic study (study...

Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

The purpose of this study is to learn more about Gaucher disease. The information we collect from medical histories and a blood sample from people with Gaucher disease may help us pinpoint...

International Collaborative Gaucher Group (ICGG) Gaucher Registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespectiv...

Search BioPortfolio:
Advertisement
Advertisement